Abstract
A turbulent coagulation system is a prominent feature of Coronavirus Disease 2019 (COVID-19), with venous thromboembolism (VTE) a leading cause of death. Our hypothesis is that patients with inherited hypocoagulability, like congenital bleeding disorders (CBD), enjoy a protective effect against COVID-19-induced hypercoagulability and related fatal consequences. Our primary and follow-up observations revealed this effect, at least among patients with moderate to severe congenital bleeding disorders, particularly coagulation factor deficiencies. Theoretically, patients with inherited hypocoagulobility have only a potential protective effect against COVID-19-related hypercoagulability. Yet the lower rate of morbidity and mortality in patients with CBDs suggests that hypercoagulability and thrombotic events are the main cause of death in COVID-19. Therefore, appropriate and timely administration of anticoagulants could significantly decrease the rate of morbidity and mortality in COVID-19.
Keywords: COVID-19, hypercoagulability, hypocoagulability, thrombosis, congenital bleeding disorders, SARS-CoV-2.
[1]
Center for Systems Science and Engineering (CSSE) at Johns Hopkins University 16 (JHU) Coronavirus COVID-19 Global Cases. Available from:. www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
[2]
Wang, C.; Sun, S.; Sylvia, S.; Rozelle, H. Raat, Zhou, H. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: A scoping review. Infect. Dis. Poverty, 2020, 17(9), 29.
[3]
Dorgalaleh, A.; Baghaipour, M.R.; Tabibian, S.; Ghazizadeh, F.; Dabbagh, A.; Bahoush, G.; Jazebi, M.; Bahraini, M.; Fazeli, A.; Baghaipour, N.; Yousefi, F. Gastrointestinal bleeding in a newborn common clinical feature between a rare disorder and a new, common infection. Int. J. Lab. Hematol., 2020, 42(6), e277-e279.
[http://dx.doi.org/10.1111/ijlh.13318] [PMID: 32845081]
[http://dx.doi.org/10.1111/ijlh.13318] [PMID: 32845081]
[4]
Tang, N.; Li, D.; Wang, X.; Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost., 2020, 18(4), 844-847.
[http://dx.doi.org/10.1111/jth.14768] [PMID: 32073213]
[http://dx.doi.org/10.1111/jth.14768] [PMID: 32073213]
[5]
Rodriguez, J.J.; Munoz, O.C.; Porres-Aguilar, M.; Mukherjee, D. Thromboembolic complications in severe COVID-19: Current antithrombotic strategies and future perspectives. Cardiovasc. Hematol. Disord. Targets, 2021, 21(1), 23-29.
[http://dx.doi.org/10.2174/1871529X21666210315123347] [PMID: 33719953]
[http://dx.doi.org/10.2174/1871529X21666210315123347] [PMID: 33719953]
[6]
Wichmann, D.; Sperhake, J.P.; Lütgehetmann, M.; Steurer, S.; Edler, C.; Heinemann, A.; Heinrich, F.; Mushumba, H.; Kniep, I.; Schröder, A.S.; Burdelski, C.; de Heer, G.; Nierhaus, A.; Frings, D.; Pfefferle, S.; Becker, H.; Bredereke-Wiedling, H.; de Weerth, A.; Paschen, H.R.; Sheikhzadeh-Eggers, S.; Stang, A.; Schmiedel, S.; Bokemeyer, C.; Addo, M.M.; Aepfelbacher, M.; Püschel, K.; Kluge, S. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann. Intern. Med., 2020, 173(4), 268-277.
[http://dx.doi.org/10.7326/M20-2003] [PMID: 32374815]
[http://dx.doi.org/10.7326/M20-2003] [PMID: 32374815]
[7]
Dorgalaleh, A.; Dabbagh, A.; Tabibian, Sh.; Baghaipou, M.R.; Jazebi, M. Patients with congenital bleeding disorders appear to be less severely affected by SARS-CoV-2-inherited hypocoagulability overcoming acquired hypercoagulability of COVID-19? Semin. Thromb. Hemost., 2020, 46(7), 853-855.
[http://dx.doi.org/10.1055/s-0040-1713435] [PMID: 32557449]
[http://dx.doi.org/10.1055/s-0040-1713435] [PMID: 32557449]
[8]
Dorgalaleh, A.; Dabbagh, A.; Tabibian, Sh.; Baghaipou, M.R.; Jazebi, M. Do congenital bleeding disorders have a protective effect against COVID-19? A prospective study. Int. J. Lab. Hematol., 2021, 43(3), e124-e127.
[http://dx.doi.org/10.1111/ijlh.13413] [PMID: 33252816]
[http://dx.doi.org/10.1111/ijlh.13413] [PMID: 33252816]
[9]
Álvarez Román, M.T.; Butta Coll, N.; García Barcenilla, S.; Pérez González, L.; de la Plaza Collazo, I.; De la Corte Rodríguez, H.; Romero Garrido, J.A.; Martín Salces, M.; Rivas Pollmar, M.I.; Cebanu, T.; González-Zorrilla, E.; Acuña, P.; Monzón Manzano, E.; Rodríguez Merchán, E.C.; Trelles Martínez, R.; Blanco Bañares, M.J.; Gutiérrez Alvariño, M.; Jiménez, Y.V. Registry of patients with congenital bleeding disorders and COVID-19 in Madrid. Haemophilia, 2020, 26(5), 773-778.
[http://dx.doi.org/10.1111/hae.14089] [PMID: 32524712]
[http://dx.doi.org/10.1111/hae.14089] [PMID: 32524712]
[10]
Stefely, J.A.; Christensen, B.B.; Gogakos, T.; Cone Sullivan, J.K.; Montgomery, G.G.; Barranco, J.P.; Van Cott, E.M. Marked factor V activity elevation in severe COVID-19 is associated with venous thromboembolism. Am. J. Hematol., 2020, 95(12), 1522-1530.
[http://dx.doi.org/10.1002/ajh.25979] [PMID: 32833259]
[http://dx.doi.org/10.1002/ajh.25979] [PMID: 32833259]
[11]
Ladikou, E.E.; Sivaloganathan, H.; Milne, K.M.; Arter, W.E.; Ramasamy, R.; Saad, R.; Stoneham, S.M.; Philips, B.; Eziefula, A.C.; Chevassut, T. Von Willebrand factor (vWF): Marker of endothelial damage and thrombotic risk in COVID-19? Clin. Med. (Lond.), 2020, 20(5), e178-e182.
[http://dx.doi.org/10.7861/clinmed.2020-0346] [PMID: 32694169]
[http://dx.doi.org/10.7861/clinmed.2020-0346] [PMID: 32694169]
[12]
Karimi, M.; Haghpanah, S.; Azarkeivan, A.; Zahedi, Z.; Zarei, T.; Akhavan Tavakoli, M.; Bazrafshan, A.; Shirkavand, A.; de Sanctis, V. Prevalence and mortality due to outbreak of novel coronavirus disease (COVID-19) in β-Thalassemias: The nationwide Iranian experience. Br. J. Haematol., 2020, 190(3), e137-e140.
[http://dx.doi.org/10.1111/bjh.16911] [PMID: 32484906]
[http://dx.doi.org/10.1111/bjh.16911] [PMID: 32484906]
[13]
Martinelli, I.; De Stefano, V.; Mannucci, P.M. Inherited risk factors for venous thromboembolism. Nat. Rev. Cardiol., 2014, 11(3), 140-156.
[http://dx.doi.org/10.1038/nrcardio.2013.211] [PMID: 24419261]
[http://dx.doi.org/10.1038/nrcardio.2013.211] [PMID: 24419261]
[14]
Piran, S.; Schulman, S. Management of venous thromboembolism: An update. Thromb. J., 2016, 14(S1)(Suppl. 1), 23.
[http://dx.doi.org/10.1186/s12959-016-0107-z] [PMID: 27766049]
[http://dx.doi.org/10.1186/s12959-016-0107-z] [PMID: 27766049]
[15]
Franchini, M.; Mannucci, P.M. Direct oral anticoagulants and venous thromboembolism. Eur. Respir. Rev., 2016, 25(141), 295-302.
[http://dx.doi.org/10.1183/16000617.0025-2016] [PMID: 27581829]
[http://dx.doi.org/10.1183/16000617.0025-2016] [PMID: 27581829]
[16]
Zuo, Y.; Warnock, M.; Harbaugh, A.; Yalavarthi, S.; Gockman, K.; Zuo, M.; Madison, J.A. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. medRxiv, 2020.
[http://dx.doi.org/10.1101/2020.08.29.20184358]
[http://dx.doi.org/10.1101/2020.08.29.20184358]
[17]
Schulman, S.; El-Darzi, E.; Florido, M.H.C.; Friesen, M.; Merrill-Skoloff, G.; Brake, M.A.; Schuster, C.R.; Lin, L.; Westrick, R.J.; Cowan, C.A.; Flaumenhaft, R.; Ouwehand, W.H.; Peerlinck, K.; Freson, K.; Turro, E.; Furie, B. A coagulation defect arising from heterozygous premature termination of tissue factor. J. Clin. Invest., 2020, 130(10), 5302-5312.
[http://dx.doi.org/10.1172/JCI133780] [PMID: 32663190]
[http://dx.doi.org/10.1172/JCI133780] [PMID: 32663190]
[18]
Dorgalaleh, A.; Tabibian, S.; Hosseini, M.S.; Shams, M. Pharmacological management of rare coagulation factor deficiencies besides hemophilia. Expert Rev. Hematol., 2020, 13(8), 811-834.
[http://dx.doi.org/10.1080/17474086.2020.1796622] [PMID: 32667216]
[http://dx.doi.org/10.1080/17474086.2020.1796622] [PMID: 32667216]
[19]
Ruiz-Saez, A. Occurrence of thrombosis in rare bleeding disorders. Semin. Thromb. Hemost., 2013, 39(6), 684-692.
[http://dx.doi.org/10.1055/s-0033-1353391] [PMID: 23929306]
[http://dx.doi.org/10.1055/s-0033-1353391] [PMID: 23929306]
[20]
Thachil, J.; Srivastava, A. SARS-2 corona virus associated hemostatic lung abnormality in COVID-19: Is it pulmonary thrombosis or pulmonary embolism? Semin. Thromb. Hemost., 2020, 46(7), 777-780.
[http://dx.doi.org/10.1055/s-0040-1712155] [PMID: 32396963]
[http://dx.doi.org/10.1055/s-0040-1712155] [PMID: 32396963]
[21]
Girolami, A.; Tezza, F.; Scapin, M.; Vettore, S.; Casonato, A. Arterial and venous thrombosis in patients with von Willebrand’s disease: A critical review of the literature. J. Thromb. Thrombolysis, 2006, 21(2), 175-178.
[http://dx.doi.org/10.1007/s11239-006-5732-0] [PMID: 16622614]
[http://dx.doi.org/10.1007/s11239-006-5732-0] [PMID: 16622614]
Article Metrics
1